Alamar Biosciences, Inc. Stock 12‑Month Price Target Raised to $35.8, Implies 18% Upside
Analysts raised Alamar Biosciences' 12-month price target from $35.4 to $35.8, with a range of $31 to $45. This implies an 18% upside from the Nov. 3 closing price. The consensus rating remains 'Buy' with 4 Buys, 1 Hold, and 0 Sells.
How this was made

The 30-second read
Why it matters
Analyst consensus remains a Buy, reinforcing positive sentiment despite modest target change.
Market read
The price‑target upgrade provides a small but actionable signal for traders monitoring micro‑cap biotech stocks.
What to watch
Potential dilution from upcoming financing rounds not reflected in the target.
Background
Alamar Biosciences is a clinical‑stage biotech focused on oncology therapies.
Ticker impact
Analysts raised Alamar Biosciences' average price target to $35.8, implying ~18% upside from the recent close.
likely modest upside as investors price in the raised target
Price‑target upgrades are a direct catalyst; the 18% implied upside may attract short‑term interest.
Market effects
Small‑cap biotech sector may see slight uplift from analyst optimism.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact; confined to niche biotech investors.
Counterpoint
The target raise may be premature if upcoming trial data disappoints.
Key entities
- companyAlamar Biosciences, Inc.
Biotech firm whose price target was raised.



